Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
Abstract
BACKGROUND: Metastatic breast cancer (MBC) remains a treatable, but incurable disease. Anti-cancer treatments and supportive therapies aim to control disease, prolong survival, ameliorate physical symptoms and improve quality of life (QoL). Currently, no validated MBC-specific patient-reported outcome measures exist, and existing tools may lack specific content and sensitivity to measure the impact of MBC. This study aims to develop a European Organisation for Research and Treatment of Cancer (EORTC) module for MBC. METHODS: Development followed EORTC module guidelines. In phase 1, QoL issues were identified via systematic literature reviews and assessed by semi-structured interviews with healthcare professionals (HCPs) and patients. In phase 2, the most relevant and important issues were converted into questionnaire items using the EORTC Item Library to form the provisional module. RESULTS: The review included 103 papers (phase III clinical trials n = 70 and observational or qualitative studies n = 33), from which 185 issues were extracted, spanning physical, psychological, emotional and social domains. Interviews with 41 HCPs and 187 patients from eight countries refined this list to 44. After expert panel review, the provisional module consisted of 40 issues, assessed by 44 items (EORTC QLQ-MBR44). A sub-analysis of the EORTC QLQ-C30 revealed its content to be considered relevant to MBC by HCP and patients. CONCLUSION: The provisional EORTC MBC-specific module aims to enhance understanding and measurement of QoL in clinical research and care and be the first QoL tool dedicated to MBC. The standardised tool contains relevant QoL issues and is currently undergoing qualitative and psychometric testing.
Related
- Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
- Plasmodium rootlet SFA1 coordinates cell replication, apical polarity and cytoskeletal organisation during sexual development
- Development of Neonatal Functional Brain Network Organisation and Its Association with Childhood Neurodevelopmental Outcomes
- Extracellular matrix properties and dynamics are important for butterfly scale nanostructure development
- Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
BibTeX
@article{bedding2026which,
title = {{Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)}},
author = {Christopher Bedding and Kate Absolom and Katarzyna Pogoda and Akihiko Shimomura and Hiroto Ishiki and Juan Ignacio Arraras and Julien Peron and Monica Pinto and Nora Nevries and Omar Shamieh and Tara Chalk and Teresa Young and Vesna Bjelic-Radisic and Waleed Alrjoub and Yuichiro Kikawa and Fatima Cardoso and Galina Velikova},
journal = {The Breast},
year = {2026},
month = oct,
doi = {10.1016/j.breast.2026.104911},
url = {https://hal.science/hal-05799850v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
AU - Christopher Bedding
AU - Kate Absolom
AU - Katarzyna Pogoda
AU - Akihiko Shimomura
AU - Hiroto Ishiki
AU - Juan Ignacio Arraras
AU - Julien Peron
AU - Monica Pinto
AU - Nora Nevries
AU - Omar Shamieh
AU - Tara Chalk
AU - Teresa Young
AU - Vesna Bjelic-Radisic
AU - Waleed Alrjoub
AU - Yuichiro Kikawa
AU - Fatima Cardoso
AU - Galina Velikova
PY - 2026
DA - 2026/10/14
JO - The Breast
DO - 10.1016/j.breast.2026.104911
UR - https://hal.science/hal-05799850v1
AB - BACKGROUND: Metastatic breast cancer (MBC) remains a treatable, but incurable disease. Anti-cancer treatments and supportive therapies aim to control disease, prolong survival, ameliorate physical symptoms and improve quality of life (QoL). Currently, no validated MBC-specific patient-reported outcome measures exist, and existing tools may lack specific content and sensitivity to measure the impact of MBC. This study aims to develop a European Organisation for Research and Treatment of Cancer (EORTC) module for MBC. METHODS: Development followed EORTC module guidelines. In phase 1, QoL issues were identified via systematic literature reviews and assessed by semi-structured interviews with healthcare professionals (HCPs) and patients. In phase 2, the most relevant and important issues were converted into questionnaire items using the EORTC Item Library to form the provisional module. RESULTS: The review included 103 papers (phase III clinical trials n = 70 and observational or qualitative studies n = 33), from which 185 issues were extracted, spanning physical, psychological, emotional and social domains. Interviews with 41 HCPs and 187 patients from eight countries refined this list to 44. After expert panel review, the provisional module consisted of 40 issues, assessed by 44 items (EORTC QLQ-MBR44). A sub-analysis of the EORTC QLQ-C30 revealed its content to be considered relevant to MBC by HCP and patients. CONCLUSION: The provisional EORTC MBC-specific module aims to enhance understanding and measurement of QoL in clinical research and care and be the first QoL tool dedicated to MBC. The standardised tool contains relevant QoL issues and is currently undergoing qualitative and psychometric testing.
SN - 0960-9776
SN - 1532-3080
ER -